BRIEF published on 01/15/2025 at 07:35, 1 year 3 months ago GenSight Biologics publie les résultats à long terme de LUMEVOQ® Thérapie Génique GenSight Biologics LUMEVOQ® Acuité Visuelle Neuropathie Optique Héréditaire De Leber
BRIEF published on 01/15/2025 at 07:35, 1 year 3 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats cliniques à 5 ans de la thérapie génique LUMEVOQ chez les patients atteints de NOHL, démontrant une amélioration bilatérale de l'acuité visuelle et un profil de sécurité favorable Thérapie Génique GenSight Biologics NOHL LUMEVOQ Résultats Cliniques
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 3 months ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
BRIEF published on 01/13/2025 at 11:31, 1 year 3 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 1 year 3 months ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 1 year 4 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 1 year 4 months ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
Published on 05/09/2026 at 01:30, 19 hours 7 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 20 hours 37 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/09/2026 at 19:05, 1 hour 32 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 23 hours 59 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 1 hour ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 1 hour ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 1 hour ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 1 hour ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 1 hour ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 1 hour ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 1 hour ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
